# A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT07667868** · PHASE1 · NOT_YET_RECRUITING · sponsor: **BrightPath Biotherapeutics Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma (RRMM)

## Interventions

- **BIOLOGICAL:** BP2202

## Key facts

- **NCT ID:** NCT07667868
- **Lead sponsor:** BrightPath Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667868, "A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07667868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*